David J. Nagel

800 total citations
21 papers, 559 citations indexed

About

David J. Nagel is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, David J. Nagel has authored 21 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in David J. Nagel's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Pulmonary Hypertension Research and Treatments (5 papers) and Phosphodiesterase function and regulation (4 papers). David J. Nagel is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Pulmonary Hypertension Research and Treatments (5 papers) and Phosphodiesterase function and regulation (4 papers). David J. Nagel collaborates with scholars based in United States, China and Japan. David J. Nagel's co-authors include Yan Chen, Yujun Cai, Guoyong Yin, R.M. Kottmann, Ning Zhang, Bradford C. Berk, Peter A. Knight, Clint L. Miller, Pingjin Gao and Patricia J. Sime and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Circulation Research.

In The Last Decade

David J. Nagel

19 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David J. Nagel United States 11 379 148 86 85 58 21 559
Wenyuan Zhao United States 17 517 1.4× 199 1.3× 75 0.9× 65 0.8× 37 0.6× 32 912
Hajime Abe Japan 15 264 0.7× 96 0.6× 107 1.2× 55 0.6× 22 0.4× 50 707
Frank S. Zollmann Germany 11 333 0.9× 141 1.0× 37 0.4× 152 1.8× 34 0.6× 21 621
Mariela Méndez United States 13 296 0.8× 123 0.8× 30 0.3× 57 0.7× 159 2.7× 20 564
Bo Youn Choi South Korea 9 260 0.7× 84 0.6× 31 0.4× 74 0.9× 29 0.5× 15 436
Hiromi Hiyoshi Japan 13 285 0.8× 193 1.3× 29 0.3× 67 0.8× 32 0.6× 17 516
Talat Afroze Canada 12 261 0.7× 102 0.7× 28 0.3× 71 0.8× 43 0.7× 20 512
Emilie Roudier Canada 16 427 1.1× 72 0.5× 91 1.1× 214 2.5× 33 0.6× 32 809
Tsuyoshi Kakita Japan 10 593 1.6× 269 1.8× 41 0.5× 90 1.1× 19 0.3× 11 773

Countries citing papers authored by David J. Nagel

Since Specialization
Citations

This map shows the geographic impact of David J. Nagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Nagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Nagel more than expected).

Fields of papers citing papers by David J. Nagel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Nagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Nagel. The network helps show where David J. Nagel may publish in the future.

Co-authorship network of co-authors of David J. Nagel

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Nagel. A scholar is included among the top collaborators of David J. Nagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Nagel. David J. Nagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shi, X., Anthony P. Pietropaoli, & David J. Nagel. (2025). Lurbinectedin-induced Pneumonitis and DAH in Recurrent Stage IV SCLC: Possible Pulmonary Toxicity From a Novel Alkylating Agent. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2751–A2751.
2.
Nagel, David J., et al.. (2024). Acute Exacerbations of Interstitial Lung Disease: Evolving Perspectives on Diagnosis and Management. 2(4). 10008–10008. 2 indexed citations
3.
Nagel, David J., et al.. (2022). Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respiratory Research. 23(1). 377–377. 8 indexed citations
4.
Nagel, David J., et al.. (2022). Ogerin mediated inhibition of TGF-β(1) induced myofibroblast differentiation is potentiated by acidic pH. PLoS ONE. 17(7). e0271608–e0271608. 9 indexed citations
5.
Nagel, David J., et al.. (2022). The Novel Small Molecule BTB Inhibits Pro-Fibrotic Fibroblast Behavior though Inhibition of RhoA Activity. International Journal of Molecular Sciences. 23(19). 11946–11946. 3 indexed citations
6.
7.
Croft, Daniel P., David S. Burton, David J. Nagel, et al.. (2021). The effect of air pollution on the transcriptomics of the immune response to respiratory infection. Scientific Reports. 11(1). 19436–19436. 20 indexed citations
8.
Nagel, David J., Jennifer Judge, Shannon H. Lacy, et al.. (2020). The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops. European Respiratory Journal. 56(5). 2000075–2000075. 16 indexed citations
9.
Nagel, David J., et al.. (2019). VEGF Down-Regulates OGR1 in Pulmonary Fibrosis and Induces Myofibroblast Differentiation. A5327–A5327. 1 indexed citations
10.
Judge, Jennifer, David J. Nagel, Kristina M. Owens, et al.. (2018). Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol. PLoS ONE. 13(5). e0197936–e0197936. 48 indexed citations
11.
Cai, Yujun, David J. Nagel, Qian Zhou, et al.. (2015). Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia. Circulation Research. 116(7). 1120–1132. 81 indexed citations
12.
Nagel, David J., et al.. (2014). Evidence from LENR Experiments for Bursts of Heat, Sound, EM Radiation and Particles and for Micro-explosions. Journal of Condensed Matter Nuclear Science. 13(1). 1 indexed citations
13.
Cai, Yujun, Clint L. Miller, David J. Nagel, et al.. (2010). Cyclic Nucleotide Phosphodiesterase 1 Regulates Lysosome-Dependent Type I Collagen Protein Degradation in Vascular Smooth Muscle Cells. Arteriosclerosis Thrombosis and Vascular Biology. 31(3). 616–623. 21 indexed citations
14.
15.
Zhang, Ning, Weihua Cai, Guoyong Yin, David J. Nagel, & Bradford C. Berk. (2009). GIT1 is a novel MEK1–ERK1/2 scaffold that localizes to focal adhesions. Cell Biology International. 34(1). 41–47. 22 indexed citations
16.
Miller, Clint L., Masayoshi Oikawa, Yujun Cai, et al.. (2009). Role of Ca 2+ /Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy. Circulation Research. 105(10). 956–964. 138 indexed citations
17.
Dresse, Menayit Tamrat, Doris Mayr, Volker Heinemann, et al.. (2009). HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer. Journal of Clinical Oncology. 27(15_suppl). e11500–e11500. 4 indexed citations
18.
Yang, Chengwei, Yongxin Ren, Feng Liu, et al.. (2008). Ischemic preconditioning suppresses apoptosis of rabbit spinal neurocytes by inhibiting ASK1–14-3-3 dissociation. Neuroscience Letters. 441(3). 267–271. 20 indexed citations
19.
Nagel, David J., Toru Aizawa, Weimin Liu, et al.. (2006). Role of Nuclear Ca 2+ /Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival. Circulation Research. 98(6). 777–784. 92 indexed citations
20.
Stieber, P, Hans‐Joachim Stemmler, Henri Schmidt, et al.. (2005). The pattern of HER-2/neu release in benign and malignant diseases. Journal of Clinical Oncology. 23(16_suppl). 618–618. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenyuan Zhao Breakdown of academic impact, for papers by Hajime Abe Breakdown of academic impact, for papers by Frank S. Zollmann Breakdown of academic impact, for papers by Mariela Méndez Breakdown of academic impact, for papers by Bo Youn Choi Breakdown of academic impact, for papers by Hiromi Hiyoshi Breakdown of academic impact, for papers by Talat Afroze Breakdown of academic impact, for papers by Emilie Roudier Breakdown of academic impact, for papers by Tsuyoshi Kakita
Rankless by CCL
2026